Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeutics

ABSTRACT: Abstract Diffuse midline glioma (DMG) is a pediatric cancer that originates in the midline structures of the brain. Prognosis of DMG patients remains poor due to the infiltrative nature of these tumors and the protection they receive from systemically delivered therapeutics via an intact blood–brain barrier (BBB), making treatment difficult. While the cell of origin remains disputed, it is believed to reside in the ventral pons. Recent research has pointed toward epigenetic dysregulation inducing an OPC-like transcriptomic signature in DMG cells. This epigenetic dysregulation is typically caused by a mutation (K27M) in one of two histone genes—H3F3A or HIST1H3B –and can lead to a differentiation block that increases these cells oncogenic potential. Standard treatment with radiation is not

SUBMITTER:  

PROVIDER: S-EPMC10162114 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature